The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L(2024) The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy Br J Cancer(in press) DOI 10.1038/s41416-024-02875-5, PubMed 39390250
Møller P, Säppäla TT, Domiguez-Valentin M, Sampson J(2024) Commentary on Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank J Med Genet(in press) DOI 10.1136/jmg-2024-110385, PubMed 39375027
Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T(2024) Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones Nat Commun, 15(1), 8579 DOI 10.1038/s41467-024-52980-5, PubMed 39362905
Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L(2024) The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy Br J Cancer(in press) DOI 10.1038/s41416-024-02875-5, PubMed 39390250
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl R, Mazzeo P, Schmidt N, Koch R, Hallek M, Chebel A, Armisen Det al.(2024) Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses Blood, 144(15), 1595-1610 DOI 10.1182/blood.2023022884, PubMed 38941598
Lamsal A, Andersen SB, Johansson I, Desgarnier MD, Wolowczyk C, Engedal N, Vietri M, Bjørkøy G, Giambelluca MS, Pettersen K(2024) Elucidating the power of arginine restriction: taming type I interferon response in breast cancer via selective autophagy Cell Commun Signal, 22(1), 481 DOI 10.1186/s12964-024-01858-6, PubMed 39380098